Global DOLs in Type 2 Diabetes

A curated anthology of 2023’s top 50 DOLs around the world in type 2 diabetes who are shaping attitudes, prescribing behaviours, and policy from CREATION.co, the original Digital Opinion Leader (DOL) experts.

Enquire now to find out more

The comprehensive report provides key learnings on each of the top 50 Digital Opinion Leaders in type 2 Diabetes

Assessment of their reach and influence within the eHCP community.
Summary of network dynamics.
Their digital behaviours.
Drivers and topics of interest.
Evaluation of traditional (offline) influence (KOL status).
Their current relationships with or attitudes towards the pharmaceutical industry and companies.

Find out more

This global report also includes

A detailed summary of the online HCP conversation landscape in type 2 diabetes which includes:
- Attitudes to emerging products and established brands
- Drivers of eHCP type 2 diabetes conversation
- Drivers of likelihood to prescribe
- Summary of ‘uber issues’ that impact the market
Insights from multiple online sources/channels to give a comprehensive view of the market
Examples of pharma-led DOL initiatives and engagements in type 2 diabetes

Request report sample

The Digital Opinion Leader Experts

CREATION.co work with 24 Pharma clients, including 8 of the top 10, in 38 countries.

CREATION.co delivers actionable insights in more than 56 indications / therapy areas, supporting launch medical or commercial objectives for 101 products.

Find out more

Richest ever DOL profiles

Each identified DOL is featured in a rich profile, to include:

Name and professional role; location.
Classification of topics of interest and advocacy.
HCP conversation networks (which HCPs are they talking with about type 2 diabetes?)
HCP following networks (which HCPs are following them?)
Digital behaviours.
Posting behaviour profile (why do they post?)
Reach and engagement of their posts.
Influential offline activities.
Unmet needs in type 2 diabetes.
Wider interests outside of type 2 diabetes.

Which teams can use this report?

Pharmaceutical organisations.
Medical and science communication teams – for DOL engagement planning for launch, new indications, in-line customer engagement and support; customer communication strategy, and HCP educational content shaping.
Congress excellence teams.
Brand or commercial teams – when planning for launch, new indications, in-line customer engagement.